Home Biosimilar Antibodies Others Others Demcizumab (Anti-DLL4)
For research use only. Not for use in humans.

Demcizumab (Anti-DLL4)

Synonyms: OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody

Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD.

Demcizumab (Anti-DLL4)

Quality Control

Batch: A252001 Purity: 99% Protein concentration: 5.82mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD.

Product Details

CAS No. 1243262-17-0
Molecular Weight 145.5 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.